Ventria Bioscience wins exclusion order against infringing and mislabled products from Wuhan Healthgen

Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation  Junction City, Kansas – September 14th, 2022 – Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara’s previous determination and affirmed the […]

CuraVive, the Next Generation Plant-Based Food Ingredients

New Business Unit Announcement Ventria Bioscience announces the launch of its new business unit, CuraVive. The new subsidiary is solely focused on leading the innovation in plant-based functional food ingredients. CuraVive applies over 20 years of Ventria Bioscience’s plant protein production experience to create high-performance plant-based food ingredients of unmatched quality and safety. CuraVive is […]

Ventria Bioscience Inc. Scores Key Victory in Fight Against Infringing Chinese Recombinant Albumin

For immediate release – Junction City, KS  Last week, Ventria Bioscience Inc. obtained an important win in its effort to stop the importation and sale of infringing recombinant albumin made in China by Wuhan Healthgen Biotechnology Corp. On August 18, 2021, the U.S. International Trade Commission (ITC) formally found three U.S. distributors of such products—Aspira […]

Ventria Bioscience’s ExpressTec Delivers the Power to Improve the Health Status of Children in Developing Countries

Junction City, Kansas – November 21, 2019 – A recent publication, Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries, explores the critical health benefits of synthetic human breastmilk proteins for children in developing countries. In poverty-stricken areas, children are more likely to suffer from Environmental Enteric Dysfunction (EED) […]

Biotech Manufacturing Trends from the Bioprocess International 2018 Conference

The Bioprocess International Conference, hosted by the industry-leading publication, Bioprocess International, brings people from across the world in the biotechnology field to share insight, network, and discuss the current and prospects in biologics manufacturing. This years’ conference took place September 4-7 in Boston, Massachusetts and was part of the Boston Biotech week. The conference was split into […]

Digestive Disease Week

Digestive Disease Week(DDW)  is one of the world’s largest conferences, covering a wide array of basic and clinical research topics in the fields of Inflammatory Bowel Diseases (IBD),  cancer,  and liver diseases. At this conference, several companies showcased their GI products, technology, and services for these fields. While there was a lot covered at the conference, […]

The Essential Protein Engineering Summit (PEGS)

The Essential Protein Engineering Summit took place in Boston, MA at the Seaport World Trade Center this year from April 30th – May 4th. PEGS is one of the largest conferences for biotherapeutic protein drug development with over 2,500 industry professionals joining from all over the world. This year’s conference encompassed all of the prominent industry topics including: engineering, […]

Ventria Bioscience CEO interviewed on CNBC

Ventria Bioscience CEO interviewed on CNBC about the importance of protecting scientific creativity and intellectual property. Ventria Bioscience CEO interviewed on CNBC’s Power Lunch and shared his thoughts on the importance of protecting the intellectual property and creativity of scientific innovation that drives progress in global healthcare. Watch this 4-minute video clip on CNBC.

Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year

Grant from Bill & Melinda Gates Foundation will advance Ventria’s capabilities for production of novel therapeutic proteins Junction City, Kansas – October 23, 2017 – Ventria Bioscience Inc. today announced a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli (or ETEC), […]